FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention relates to lyophilized compositions of lysyl-prolyl-threonine, in particular to lyophilized L-lysyl-D-prolyl-L-threonine compositions which are stable during storage, as well as to a method of producing said lyophilized compositions.
EFFECT: present invention refers to pharmaceutical and cosmetic compositions containing lyophilized compositions which are used in therapeutic and/or preventive treatment, for diagnosis and/or therapy of pain-related diseases, itching diseases, inflammatory diseases and/or other diseases in mammals.
7 cl, 2 dwg, 4 ex, 7 tbl
Title | Year | Author | Number |
---|---|---|---|
FORMULATIONS CONTAINING ANTIBODIES | 2009 |
|
RU2745601C2 |
NEW STABLE COMPOSITIONS FOR FXIA ANTIBODIES | 2018 |
|
RU2775692C2 |
AQUEOUS PHARMACEUTICAL COMPOSITION OF ANTIBODY TO PD-1 OF PROLGOLIMAB AND ITS USE | 2019 |
|
RU2806320C2 |
PHARMACEUTICAL COMPOSITION BASED ON IL-15 PROTEIN COMPLEX AND APPLICATIONS THEREOF | 2018 |
|
RU2749342C1 |
PHARMACEUTICAL COMPOSITION | 2017 |
|
RU2775944C2 |
PHARMACEUTICAL COMPOSITION OF ANTI-TRBV9 ANTIBODY AND USE THEREOF | 2022 |
|
RU2826886C1 |
PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODY TO SOST, AND ITS USE | 2018 |
|
RU2779430C2 |
FORMULATIONS BASED ON CD19 ANTIBODY | 2017 |
|
RU2748024C2 |
PHARMACEUTICAL COMPOSITIONS FOR TREATING ACID SPHINGOMYELINASE DEFICIENCY | 2019 |
|
RU2826120C2 |
GM-CSF-NEUTRALIZING ANTIBODIES FOR USE IN TREATING RHEUMATOID ARTHRITIS OR AS ANALGESICS | 2014 |
|
RU2714919C2 |
Authors
Dates
2019-04-16—Published
2014-10-27—Filed